Background: Selection of the right reference gene(s) is crucial in the analysis and 14 interpretation of gene expression data. In head and neck cancer, studies evaluating 15 the efficacy of internal reference genes are rare. Here, we present data for a minimal 16 set of candidates as internal control genes for gene expression studies in head and 17 neck cancer. 18 Methods: We analyzed data from multiple sources (in house whole-genome gene 19 expression microarrays, n=21; TCGA RNA-seq, n=42, and published gene 20 expression studies in head and neck tumors from literature) to come up with a set of 21 genes (discovery set) for their stable expression across tumor and normal tissues. 22 We then performed independent validation of their expression using qPCR in 14 23 2 tumor:normal pairs. Genes in the discovery set were ranked using four different 24 algorithms (BestKeeper, geNorm, NormFinder, and comparative delta Ct) and a 25 web-based comparative tool, RefFinder, for their stability and variance in expression 26 across tissues. 27 Results: Our analyses resulted in 18 genes (discovery set) that had lowest variance 28 and high level of expression across tumor and normal samples. Independent 29 experimental validation and analyses with multiple tools resulted in top ranked five 30 genes (RPL30, RPL27, PSMC5, OAZ1 and MTCH1) out of which, RPL30 (60S 31 ribosomal protein L30) and RPL27 (60S ribosomal protein L27), performed best and 32 were abundantly expressed across tumor and normal tissues. 33 Conclusions: RPL30 and RPL27 are stably expressed in HNSCC and should be 34 used as internal control genes in gene expression in head and neck tumors studies. 35 36
high-throughput data like microarrays and RNA-seq, the confirmation of their 3 expression using qPCR across tumor and normal samples are absent. Past studies 49 argue the lack of uniformity of expression on internal control genes based on 50 experimental conditions 5 6 . Therefore, it is crucial that the expression of internal 51 control genes remains unaltered across temporal, spatial and experimental 52 conditions. Additionally, internal control genes need to take into account genes 53 expressed both at high and low level of expression. Availability of high-throughput 54 gene expression data from different cohorts and large consortia like TCGA warrants 55 revisiting the validity of widely used genes like ACTB, TUBB and GAPDH. 56 In the present study, we analyzed HNSCC gene expression data from three 57 sources; in house microarray data, TCGA RNA-seq data and data from literature to 58 come up with a set of genes (discovery set) that are stably and robustly expressed 59 with least variance across tumor:normal pairs. We subsequently validated the 60 expression of the discovery set in tumor:normal pairs (n=14) independently using 61 qPCR. Finally we obtained a list of two genes as a minimal set by comparing and 62 ranking their expression during validation. 4 transformed and normalized using VST (Variance Stabilizing Transformation) and 73 LOESS methods, respectively, using lumi 7 and top genes with least across-sample 74 variance in expression were selected. Genes with fold change between 0.95-1.05 75 (tumor/normal) and with standard deviation < 0.05 for the fold changes were selected 76 further. 77 RNA-seq data processing 78 RSEM-processed RNA-Seq gene expression values ( 
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The schema for selecting genes for discovery set is depicted in Figure 1 . After 138 analyzing data from all sources, 18 genes were selected that had least variance 139 across all the tumor and normal samples, were well annotated and had some biology 140 known (Table 1A and Supplementary Table 1 ). Genes in the validation tumor:normal 141 pairs, we produced standard curves reflecting the linear regression (R 2 >0.9) and 142 amplification efficiency ( Supplementary Figure 1 ). Primers for all the genes showed 143 specific amplifications as shown by the dissociation curves in Supplementary Figure  7 2. Data from qPCR validation of genes ( Figure 2A ) showed variable levels of 145 expression for the 18 genes in different validation samples. As Figure 2B indicates, 146 results from the four different algorithms (Genorm, Normfinder, Bestkeeper & 147 Comparative Ct) and a comprehensive RefFinder tool showed expression of 5 genes 148 (RPL30, RPL27, PSMC5, OAZ1 and MTCH1) were highly consistent across all the 149 samples among the discovery panel. Further, we ranked the genes using the above 150 tools ( Figure 2B) all the tumor and normal samples with least variance (Figure 2A ). Therefore, we term This gene encodes a ribosomal protein that is a component of the 60S subunit. The protein belongs to the L30E family of ribosomal proteins. It is located in the cytoplasm. This gene is co-transcribed with the U72 small nucleolar RNA gene, which is located in its fourth intron. As is typical for genes encoding ribosomal proteins, there are multiple processed pseudogenes of this gene dispersed through the genome. This gene encodes a ribosomal protein that is a component of the 40S subunit and a member of the S14P family of ribosomal proteins. The protein, which contains a C2-C2 zinc finger-like domain that can bind to zinc, can enhance the tumor suppressor activity of Ras-related protein 1A (KREV1). It is located in the cytoplasm. Variable expression of this gene in colorectal cancers compared to adjacent normal tissues has been observed, although no correlation between the level of expression and the severity of the disease has been found. As is typical for genes encoding ribosomal proteins, there are multiple processed pseudogenes of this gene dispersed through the genome. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.RPS29 (Ribosomal Protein S29) is a Protein Coding gene. Diseases associated with RPS29 include diamond-blackfan anemia 13 and diamond-blackfan anemia. Among its related pathways are Viral mRNA Translation and Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S. GO annotations related to this gene include structural constituent of ribosome.
https://www.ncbi.nlm.nih.gov/gene/6235 OAZ1 The protein encoded by this gene belongs to the ornithine decarboxylase antizyme family, which plays a role in cell growth and proliferation by regulating intracellular polyamine levels. Expression of antizymes requires +1 ribosomal frameshifting, which is enhanced by high levels of polyamines. Antizymes in turn bind to and inhibit ornithine decarboxylase (ODC), the key enzyme in polyamine biosynthesis; thus, completing the auto-regulatory circuit. This gene encodes antizyme 1, the first member of the antizyme family, that has broad tissue distribution, and negatively regulates intracellular polyamine levels by binding to and targeting ODC for degradation, as well as inhibiting polyamine uptake. Antizyme 1 mRNA contains two potential in-frame AUGs; and studies in rat suggest that alternative use of the two translation initiation sites results in N-terminally distinct protein isoforms with different subcellular localization. Alternatively spliced transcript variants have also been noted for this gene.
https://www.ncbi.nlm.nih.gov/gene/4946 Supplementary Table 1 : Genes selected in the discovery set and their function.
